Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: Is there a survival benefit? A systematic review

Table 3 Synchronous isolated liver metastases resection outcomes vs controls

Ref.		Treatment modality	n of patients	Median age	n of mets	Max met diameter	Adjuvant chemotherapy	OS	P value
Dünschede et al[23], 2010	Control	Gemcitabine, no surgical resection	5	63	1	3.5 (1-9)	NR	Median 11 mo	NR
	Intervention	Synchronous resection of pancreatic primary and liver metastases	9	55	3	Mean 3.5 cm	NR	Median 8 mo
Klein et al[25], 2012	Control	Pancreatic primary resection only. No liver metastases	22	Mean 57.5	-	-	22 (100)	Median 14.6 mo	0.015
	Intervention	Synchronous resection of pancreatic primary and liver metastases	22	Mean 57.5	-	-	22 (100)	Median 7.6 mo
Shi et al[32], 2016	Control	Palliative bypass and gemcitabine	39	Mean 63	-	-	NR	Median 16.9 mo	0.085
	Intervention	Synchronous resection of pancreatic primary and liver metastases	30	Mean 62.2	-	-	NR	Median 15.7 mo
Tachezy et al[27], 2016	Control	No resection, palliative bypass/exploration and chemotherapy (FOLFIRINOX or Gemcitabine)	69	Median 62	2 (1-8)	-	58 (84)	Median 7.5 mo	< 0.001
	Intervention	Synchronous resection of pancreatic primary and liver metastases	69	Median 65	2 (1-11)	-	58 (84)	Median 14.5 mo
Yang et al[29], 2020	Control	Systemic gemcitabine-based chemotherapy, no surgery	31	Mean 61.1	-	-	NR	Median 7.6 mo	0.37
	Intervention	Synchronous resection of pancreatic primary and liver metastases	48	Mean 61.1	-	-	NR	Median 7.8 mo

NR: Not reported; OS: Overall survival.